Status:
COMPLETED
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
Lead Sponsor:
Biogen
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate whether the drug BG00012 can improve the symptoms of rheumatoid arthritis (RA) in patients who are already taking methotrexate for RA, but who still suffer ...
Detailed Description
The study is a double-blind, placebo-controlled study of BG00012 plus methotrexate, versus methotrexate alone, in patients with active RA, who have had an incomplete response to other conventional dis...
Eligibility Criteria
Inclusion
- must be taking methotrexate
- inadequate response to at least one conventional DMARD
- swollen and tender joint count
Exclusion
- previous treatment with TNF or any other biologic or prosorba column
- Other criteria also apply.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT00810836
Start Date
December 1 2008
End Date
March 1 2010
Last Update
September 16 2013
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Woolloongabba, Queensland, Australia, 4102
2
Research Site
Woodville, South Australia, Australia, 5011
3
Research Site
Sarnia, Ontario, Canada, N7T4X3
4
Research Site
New Market, Canada